Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

被引：0
|
作者：
Michelino De Laurentiis
Simona Borstnar
Mario Campone
Ellen Warner
Javier Salvador Bofill
William Jacot
Susan Dent
Miguel Martin
Alistair Ring
Paul Cottu
Janice Lu
Eva Ciruelos
Hamdy A. Azim
Sanjoy Chatterjee
Katie Zhou
Jiwen Wu
Lakshmi Menon-Singh
Claudio Zamagni
机构：
[1] Istituto Nazionale Tumori IRCCS “Fondazione Pascale”,Division of Breast Medical Oncology, Department of Breast and Thoracic Oncology Director
[2] Institute of Oncology Ljubljana,Gregorio Marañón General University Hospital, GEICAM
[3] Western Cancer Institute,University Hospital 12 de Octubre
[4] Sunnybrook Health Sciences Centre,Faculty of Medicine
[5] Virgen del Rocío University Hospital,Duke Cancer Institute
[6] Biomedicine Institute,undefined
[7] Montpellier Cancer Institute,undefined
[8] The Ottawa Hospital Cancer Centre,undefined
[9] Universidad Complutense,undefined
[10] CIBERONC,undefined
[11] Royal Marsden Hospital NHS Foundation Trust,undefined
[12] Curie Institute,undefined
[13] USC Norris Comprehensive Cancer Center,undefined
[14] Clara Campal Comprehensive Cancer Center (HM CIOCC),undefined
[15] Cairo University,undefined
[16] Tata Medical Center,undefined
[17] Novartis Pharmaceuticals Corporation,undefined
[18] Azienda Ospedaliero-Universitaria Di Bologna,undefined
[19] Duke University School of Medicine,undefined
来源：
Breast Cancer Research and Treatment | 2022年 / 191卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：223 / 224
页数：1
相关论文
共 50 条
  • [31] Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study
    Masuda, Norikazu
    Nishimura, Reiki
    Takahashi, Masato
    Inoue, Kenichi
    Ohno, Shinji
    Iwata, Hiroji
    Mori, Yuko
    Hashigaki, Satoshi
    Muramatsu, Yasuaki
    Nagasawa, Takashi
    Umeyama, Yoshiko
    Toi, Masakazu
    CANCER SCIENCE, 2018, 109 (03): : 803 - 813
  • [32] Preliminary results of a phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer
    Kozloff, M.
    Chuang, E.
    Roy, J.
    Starr, A.
    Gowland, P. A.
    Tarpey, M. J.
    Collier, M.
    Verkh, L.
    Kern, K.
    Miller, K.
    EJC SUPPLEMENTS, 2007, 5 (04): : 216 - 216
  • [33] Preliminary results of a phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer
    Kozloff, Mark
    Chuang, Ellen
    Roy, Jessica
    Starr, Alexander
    Gowland, Patricia A.
    Tarpey, Matthew J.
    Collier, Mary
    Verkh, Lev
    Kern, Kenneth
    Miller, Kathy
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3591S - 3591S
  • [34] Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial
    Mario Campone
    Michelino De Laurentiis
    Claudio Zamagni
    Igor Kudryavcev
    Mariëtte Agterof
    Ursa Brown-Glaberman
    Markéta Palácová
    Sanjoy Chatterjee
    Lakshmi Menon-Singh
    Jiwen Wu
    Miguel Martín
    Breast Cancer Research and Treatment, 2022, 193 : 95 - 103
  • [35] Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial
    Campone, Mario
    De Laurentiis, Michelino
    Zamagni, Claudio
    Kudryavcev, Igor
    Agterof, Mariette
    Brown-Glaberman, Ursa
    Palacova, Marketa
    Chatterjee, Sanjoy
    Menon-Singh, Lakshmi
    Wu, Jiwen
    Martin, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 193 (01) : 95 - 103
  • [36] Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptorepositive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study
    Decker, T.
    Fasching, P. A.
    Nusch, A.
    Hartkopf, A.
    Heinrich, B. J.
    Kurbacher, C. M.
    Fuchs, R.
    Tesch, H.
    Krabisch, P.
    Huober, J.
    Kuemmel, S.
    Brucker, S. Y.
    Janni, W.
    Schneeweiss, A.
    Schuler, M.
    Fehm, T. N.
    Lueftner, D.
    Quiering, C.
    Kreuzeder, J.
    Reinisch, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S467 - S468
  • [37] Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study
    Im, Seock-Ah
    Mukai, Hirofumi
    Park, In Hae
    Masuda, Norikazu
    Shimizu, Chikako
    Kim, Sung-Bae
    Im, Young-Hyuck
    Ohtani, Shoichiro
    Bartlett, Cynthia Huang
    Lu, Dongrui R.
    Iyer, Shrividya
    Mori, Yuko
    Mori, Ave
    Gauthier, Eric
    Finn, Richard S.
    Toi, Masakazu
    JOURNAL OF GLOBAL ONCOLOGY, 2019, 5 : 1 - 19
  • [38] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population
    Salvador, J.
    Ciruelos, E. M.
    Prat, A.
    Jimenez-Rodriguez, B.
    de la Cruz, L.
    Martinez, N.
    Villanueva Vazquez, R.
    de Toro, R.
    Anton, A.
    Moreno, F.
    Alvarez, I.
    Gavila, J.
    Quiroga, V.
    Vicente, E.
    de la Haba, J.
    Gonzalez-Santiago, S.
    Diaz, N.
    Barnadas, A.
    Cantos Sanchez de Ibarguen, B.
    Delgado, J. I.
    Bellet, M.
    Gimeno, A.
    Sanz, S.
    Martin, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [39] Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:: Analysis of survival and update of efficacy from the international letrozole breast cancer group
    Mouridsen, H
    Gershanovick, M
    Sun, Y
    Pérez-Carrión, R
    Boni, C
    Monnier, A
    Apffelstaedt, J
    Smith, R
    Sleeboom, HP
    Jaenicke, F
    Pluzanska, A
    Dank, M
    Becquart, D
    Bapsy, PP
    Salminen, E
    Snyder, R
    Chaudri-Ross, H
    Lang, R
    Wyld, P
    Bhatnagar, A
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) : 2101 - 2109
  • [40] Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the international letrozole breast cancer group
    Buzdar, AU
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) : 3199 - 3200
12345